



6P1614
RECEIVED
JUN 18 2002
TECH CENTER 1600/2300

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT**

Docket Number:
11245/46902

Application Number
10/040,128

Filing Date
January 2, 2002

Examiner
To Be Assigned

Art Unit
1614

Invention Title
**ANTIBODY ANTAGONISTS OF VE-CADHERIN
WITHOUT ADVERSE EFFECTS ON VASCULAR
PERMEABILITY**

Inventor(s)
LIAO et al.

Address to:
Commissioner for Patents
Washington D.C. 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents & Trademarks, Washington, D.C. 20231.



Date: 6/5/02
Signature: *Lawrence P. Casson*
Lawrence P. Casson, Reg. No. 46,606

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: 6/5/02

By: *Lawrence P. Casson*
Lawrence P. Casson (Reg. No. 46,606)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANTS
PTO FORM 1449**

Atty. Docket No.
11245/46902

Serial No.
10/040,128

Applicant(s)
LIAO et al.

Filing Date
January 2, 2002

Group
1614

U. S. PATENT DOCUMENTS


EXAMINER'S INITIALS	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
	5,597,725	January 28, 1997	Suzuki			

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS

EXAMINER'S INITIALS	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Carmeliet et al., "Targeted Deficiency or Cytosolic Truncation of the VE-cadherin Gene in Mice Impairs VEGF-Mediated Endothelial Survival and Angiogenesis," Cell, Vol. 98, July 23, 1999, pp. 147-157.
	Vittet et al., "Targeted Null-mutation in the Vascular Endothelial-Cadherin Gene Impairs the Organization of Vascular-like Structures in Embryoid Bodies," Proc. Natl. Acad. Sci. USA, Vol. 94, June 1997, pp. 6273-6278.
	Caveda et al., "Inhibition of Cultured Cell Growth by Vascular Endothelial Cadherin (Cadherin-5/VE-Cadherin)," J. Clin. Invest., Vol. 98, No. 4, August 1996, pp. 886-893.
	Corada et al., "Vascular Endothelial-cadherin is an Important Determinant of Microvascular Integrity In Vivo," Proc. Natl. Acad. Sci. USA, Vol. 96, August 1999, pp. 9815-9820.
	Uemura et al., "The Cadherin Superfamily at the Synapse: More Members, More Missions," Cell, Vol. 93, June 26, 1998, pp. 1095-1098.
	Bach et al., "VE-Cadherin Mediates Endothelial Cell Capillary Tube Formation in Fibrin and Collagen Gels," Experimental Cell Research, Vol. 238, no. 2, 1998, pp. 324-334.
	Breier et al., "Molecular Cloning and Expression of Murine Vascular Endothelial-Cadherin in Early Stage Development of Cardiovascular System," Blood, Vol. 87, No. 2, January 15, 1996, pp. 630-641.
	Maschio et al., "Polymorphonuclear Leukocyte Adhesion Triggers the Disorganization of Endothelial Cell-to-Cell Adherens Junctions," The Journal of Cell Biology, Vol. 135, No. 2, October 1996, pp. 497-510.
	Martin-Padura et al., "Functional Adhesion Molecule, a Novel Member of the Immunoglobulin Superfamily that Distributes at Intercellular Junctions and Modulates Monocyte Transmigration," The Journal of Cell Biology, Vol. 142, No. 1, July 13, 1998, pp. 117-127.
	Liao et al., "Identification of antibody-based VE-cadherin antagonists for the application of anti-angiogenesis therapy," Proc. Nat'l Acad. Sci. USA, vol. 41, March 2000, abstract #4096
	Breviario et al., "Functional properties of human vascular endothelial cadherin (7B4/cadherin-5), and endothelium-specific cadherin," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15, no. 8, August 1995, pp. 1229-1239



EXAMINER'S INITIALS	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Haselton et al., "Role of cadherins 5 and 13 in the aortic endothelial barrier," Journal of Cellular Physiology, vol. 171, no. 3, June 1997, pp. 243-251
	Corada et al., "Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability," Blood, vol. 97, no. 6, March 15, 2001, pp. 1679-1684
	Takeichi, Ann. Rev. Biochem. (1990), 59:237-252
	Geiger & Ayalon, Ann. Rev. Cell Biol. (1992), 8:302-332
	Nose et al., Cell (1988), 54:993-1001
	Shapiro et al., Nature (1996), 374:327-337
	Lampugnani et al., J. Cell. Biol. (1992), 118:1511-1522
	Rabiet et al., Arterioscler. Thromb. Vasc. Biol. (1996), 16:488-496
	Dejana, J. Clin. Invest. (1997), 100:S7-10
	Dejana et al., FASEB J. (1995), 9:910-918
	Dejana et al., Ann NY Acad Sci. (1997), 811:36-43
	Kevil et al., J. Biol. Chem. (1988) 273:15099-15103
	Yap et al., J. Cell Biol. (1998), 141:779-789
	Faure et al., Development (1999), 128: 2093-2101

RECEIVED
JUN 18 2002
TECH CENTER 1600/2900

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

NY01 463949